DANYELZA NAXITAMAB
Live / Registered — Registered (as of 08 Dec 2020)
What this means for you
Registered since 08 Dec 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88749157
- Registration number
- 6214682
- Mark type
- Design + words
- Filed
- 07 Jan 2020
- Published for opposition
- 22 Sept 2020
- Registered
- 08 Dec 2020
- Attorney of record
- Andrew N. Spivak
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer
- Class 042 — Scientific and technological services: Research and development services in the field of antibodies; research and development services in the field of antibody technology; laboratory research and analysis services relating to the production of antibodies; scientific and technological services, namely, scientific research, analysis, and testing in the field of antibodies, and research and design relating thereto; industrial analysis and research services in the field of antibodies
Owner
- Y-mAbs Therapeutics, Inc, New York, NY, US
- Y-mAbs Therapeutics, Inc, New York, NY, US
- Y-mAbs Therapeutics, Inc, New York, NY, US
Prosecution history
- 08 Dec 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 08 Dec 2020 — REGISTERED-PRINCIPAL REGISTER
- 22 Sept 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 22 Sept 2020 — PUBLISHED FOR OPPOSITION
- 02 Sept 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 19 Aug 2020 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 18 Aug 2020 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 18 Aug 2020 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 18 Aug 2020 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 21 Jul 2020 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 21 Jul 2020 — NON-FINAL ACTION E-MAILED
- 21 Jul 2020 — NON-FINAL ACTION WRITTEN
- 20 Jul 2020 — PREVIOUS ALLOWANCE COUNT WITHDRAWN
- 23 Jun 2020 — WITHDRAWN FROM PUB - OG REVIEW QUERY
- 10 Jun 2020 — ELECTRONIC RECORD REVIEW COMPLETE